Two industry heavyweights team up to give dry AMD therapy a global jolt.
A new alliance is shining fresh light on one of ophthalmology’s toughest challenges: dry age-related macular degeneration (dry AMD). MacuMira Medical Devices (Calgary, Canada) and Keeler (Windsor, UK), a manufacturer with over a century of experience, have announced a collaboration to expand global access to MacuMira’s non-invasive microcurrent retinal therapy.
The partnership kicks off with a launch in Australia and New Zealand at the upcoming RANZCO (Royal Australian and New Zealand College of Ophthalmology) meeting, with more markets expected to follow soon after.
READ MORE: Study Links Instant Coffee to Increased Risk of Age-Related Macular Degeneration
How it works
The MacuMira device delivers precise, low-level electrical currents that gently activate the retinal pigment epithelium (RPE) cells, which are vital caretakers that nourish and maintain the retina. By stimulating these cells, the therapy enhances mitochondrial activity, boosting their energy and resilience.
The treatment is non-invasive, performed in a clinical setting in just 32 minutes.
Clinical trials have reported improvements in visual acuity and contrast sensitivity, suggesting real potential to restore, not merely maintain, visual function.*
READ MORE: EURETINA 2025: What’s Next in the Neovascular AMD Playbook
Keeler’s role in taking it global
Founded in 1917, Keeler has spent over a century perfecting precision ophthalmic instruments. With its established manufacturing and distribution network, the company will help bring the MacuMira device to Australia and New Zealand through ParagonCare (Mount Waverley, Australia)—and eventually, to a global audience.
“This partnership marks a transformative moment as we align Keeler’s heritage and reach with MacuMira’s groundbreaking therapy,” said Andy Harbidge, managing director at Keeler, in a news release. “Together, we will bring new hope to patients and clinicians worldwide”.
Thanks to this collaboration, access to an entirely new therapeutic option for dry AMD could soon extend well beyond Canada.
Epion shares the news on its LinkedIn page.
MacuMira’s mission and global vision
Since its debut in Canada in 2024, thousands of MacuMira treatments have been performed safely, showing encouraging results. Now, with Keeler’s global footprint, the company aims to make this therapy available to patients worldwide.
“By combining Keeler’s global presence with our novel science, we are redefining how this disease is managed, restoring not only vision but also dignity and independence to patients,” said Justin Sather, CEO at MacuMira.
READ MORE: Sheets, Chips & Switches: Practical Paths to Vision Restoration
With Keeler and MacuMira joining forces, ophthalmologists may soon have a non-invasive, restorative option to add to their dry AMD toolkit. The therapy’s promise lies nSoot only in protecting sight but in giving it a second chance.
As the therapy makes its debut in the RANZCO 2025, ophthalmologists alike are looking forward to a future where restoring sight could become the new standard of dry AMD care.
*Parkinson KM, Sayre EC, Tobe SW. Evaluation of visual acuity in dry AMD patients after microcurrent electrical stimulation. Int J Ret Vitr. 2023;9:36.
Editor’s Note: This content is intended exclusively for healthcare professionals. It is not intended for the general public. Products or therapies discussed may not be registered or approved in all jurisdictions, including Singapore.